

Supplemental Tables for:

Analysis of real-world data to investigate the impact of race and ethnicity on response to PD-1 and PD-L1 inhibitors in advanced NSCLC

Kristin Ayers et al.

Table S1. Cohort Follow Up Descriptive Statistics.

n=249	TTD	OS
Events (%)	142 (57.0)	91 (36.5)
<i>Died on anti PD1/PD-L1 Therapy</i>	63 (44.4)	63 (69.2)
<i>Lost to follow up after/before event*</i>	33 (23.2)	9 (9.9)
Censored (%)	107 (43.0)	158 (63.5)
<i>Censored at end of study (complete follow up)</i>	50 (46.7)	81 (51.3)
<i>Drop-out (left study before event)</i>	57 (53.3)	77 (48.7)
<i>Censored on anti PD1/PD-L1 Therapy</i>	107 (100)	99 (62.7)
<i>Censored Drop-out on anti PD1/PD-L1 Therapy</i>	57 (53.3)	47 (29.7)
<i>Censored Drop-out and likely entered Hospice</i>	21 (19.6)	31 (19.6)
TTD/OS time (including censored) >6 months	78 (31.3)	140 (56.2)
TTD/OS time (including censored) >1 year	41 (16.5)	75 (30.1)
Only one treatment (TTD=1)	40 (16.1)	

NOTE: Percentages for indented categories are based on the total number within the corresponding boldface group. *Either 1) had treatment discontinuation but were lost to follow up before the end of study or death, or 2) died but did not have a hospital visit within 120 days of death.

Supplemental Tables for:

Analysis of real-world data to investigate the impact of race and ethnicity on response to PD-1 and PD-L1 inhibitors in advanced NSCLC

Kristin Ayers et al.

Table S2. Hazard Ratios for single variable cox regression.

Group	n (%)	HR TTD (95% CI)	pval TTD	HR OS (95% CI)	pval OS
Age at Rx initiation (yrs)	249 (100)	0.99 (0.97-1.01)	0.381	1.01 (0.99-1.04)	0.244
<i>Age at Rx initiation (yrs)</i>					
< 50	7 (2.8)	1.23 (0.49-3.09)	0.654	0.88 (0.21-3.68)	0.862
50-64	92 (36.9)	Ref	-	Ref	-
65-74	96 (38.6)	1.06 (0.73-1.53)	0.776	1.11 (0.69-1.79)	0.660
75+	54 (21.7)	0.77 (0.48-1.25)	0.297	1.11 (0.63-1.93)	0.724
BMI	249 (100)	1.00 (0.97-1.02)	0.823	0.99 (0.95-1.02)	0.392
<i>Gender</i>					
Female	122 (49.0)	Ref	-	Ref	-
Male	127 (51.0)	0.92 (0.66-1.28)	0.639	1.58 (1.04-2.39)	0.033
<i>Race/Ethnicity</i>					
White	110 (44.2)	Ref	-	Ref	-
Asian	24 (9.6)	0.90 (0.51-1.57)	0.708	0.43 (0.19-1.01)	0.053
African American	75 (30.1)	0.64 (0.42-0.96)	0.032	0.58 (0.35-0.96)	0.035
Hispanic	35 (14.1)	0.94 (0.59-1.50)	0.793	0.69 (0.38-1.25)	0.217
Other/Unknown	5 (2.0)	-	-	-	-
<i>Smoking Status</i>					
Current Smoker	90 (36.1)	Ref	-	Ref	-
Former Smoker	117 (47.0)	1.18 (0.81-1.72)	0.380	1.34 (0.86-2.10)	0.201
Never Smoker	38 (15.3)	1.84 (1.14-2.96)	0.012	0.73 (0.36-1.48)	0.382
Not Reported	4 (1.6)	-	-	-	-
<i>Histology</i>					
Non-squamous cc*	189 (75.9)	Ref	-	Ref	-
Squamous cc*	48 (19.3)	0.71 (0.45-1.12)	0.141	0.90 (0.53-1.53)	0.693
NSCLC, Nos	12 (4.8)	1.43 (0.67-3.08)	0.358	1.07 (0.39-2.95)	0.889
<i>PDL1 Status</i>					
Negative	52 (20.9)	Ref	-	Ref	-
Not tested	119 (47.8)	1.15 (0.74-1.78)	0.533	1.06 (0.63-1.80)	0.822
Positive	78 (31.3)	0.94 (0.58-1.52)	0.812	0.62 (0.33-1.17)	0.143
<i>Targeted Mutation in EGFR/ALK</i>					
Mutation Absent	157 (63.1)	Ref	-	Ref	-
Mutation Present	25 (10.0)	1.20 (0.69-2.07)	0.518	1.69 (0.90-3.16)	0.102
Not tested	67 (26.9)	0.74 (0.49-1.11)	0.144	1.08 (0.67-1.76)	0.749
<i>Line of Treatment</i>					
1	113 (45.4)	Ref	-	Ref	-
2	102 (41.0)	1.08 (0.75-1.56)	0.672	1.48 (0.94-2.32)	0.089
3 or more	34 (13.7)	1.17 (0.93-1.48)	0.175	1.19 (0.89-1.58)	0.244
<i>Concurrent Chemotherapy</i>					
No	201 (80.7)	Ref	-	Ref	-
Yes	48 (19.3)	0.64 (0.41-1.01)	0.055	0.63 (0.34-1.16)	0.142

Supplemental Tables for:

Analysis of real-world data to investigate the impact of race and ethnicity on response to PD-1 and PD-L1 inhibitors in advanced NSCLC

Kristin Ayers et al.

<i>Drug</i>					
Atezolizumab	59 (24.1)	Ref	-	Ref	-
Nivolumab	84 (34.3)	0.69 (0.45-1.06)	0.091	1.32 (0.77-2.26)	0.310
Pembrolizumab	102 (41.6)	0.65 (0.43-0.99)	0.047	0.91 (0.51-1.60)	0.736
More than one	4 (1.6)	-	-	-	-
<i>Disease Comorbidities</i>					
None Reported	128 (51.4)	Ref	-	Ref	-
Asthma	44 (17.7)	0.89 (0.58-1.39)	0.618	0.80 (0.44-1.46)	0.472
COPD (inc. Emphysema)	77 (30.9)	0.67 (0.45-0.99)	0.044	1.08 (0.68-1.70)	0.752

*cell carcinoma; Rx corresponds to anti PD1/PD-L1 therapy

Supplemental Tables for:

Analysis of real-world data to investigate the impact of race and ethnicity on response to PD-1 and PD-L1 inhibitors in advanced NSCLC

Kristin Ayers et al.

Table S3. Group Characteristics Before Matching

	White	African American	p-value	SMD
n	110	75		
Clinical Variables				
BMI (mean (SD))	28.3 (6.3)	26.7 (6.2)	0.091	0.255
Age at Rx Initiation (mean (SD))	70.5 (8.2)	65.0 (9.4)	<0.001	0.610
Age at Rx Initiation in Years (%)			0.005	0.544
<50	0 (0.0)	1 (1.3)		
50-64	30 (27.3)	38 (50.7)		
65-74	49 (44.5)	24 (32.0)		
75+	31 (28.2)	12 (16.0)		
Gender (%)			1.000	0.013
Female	55 (50.0)	37 (49.3)		
Male	55 (50.0)	38 (50.7)		
Smoking Status (%)			0.030	0.443
Current Smoker	36 (32.7)	37 (49.3)		
Former Smoker	62 (56.4)	31 (41.3)		
Never Smoker	12 (10.9)	5 (6.7)		
Unknown	0 (0.0)	2 (2.7)		
Histology (%)			0.122	0.306
Non-squamous cell carcinoma	88 (80.0)	50 (66.7)		
Squamous cell carcinoma	18 (16.4)	20 (26.7)		
NSCLC, Nos	4 (3.6)	5 (6.7)		
PDL1 Status (%)			0.263	0.249
Negative	28 (25.5)	12 (16.0)		
Not tested	47 (42.7)	39 (52.0)		
Positive	35 (31.8)	24 (32.0)		
Targeted Mutation EGFR/ALK (%)			0.047	0.375
Mutation Absent	74 (67.3)	43 (57.3)		
Mutation Present	12 (10.9)	4 (5.3)		
Not tested	24 (21.8)	28 (37.3)		
Comorbidities (%)			0.012	0.444
Asthma	11 (10.0)	19 (25.3)		
COPD (including Emphysema)	46 (41.8)	21 (28.0)		
Unknown or Not reported	53 (48.2)	35 (46.7)		
Treatment Variables				
Drug (%)			0.416	0.256
Atezolizumab	24 (21.8)	22 (29.3)		
Nivolumab	40 (36.4)	20 (26.7)		
Pembrolizumab	43 (39.1)	32 (42.7)		

Supplemental Tables for:

Analysis of real-world data to investigate the impact of race and ethnicity on response to PD-1 and PD-L1 inhibitors in advanced NSCLC

Kristin Ayers et al.

More than one	3 (2.7)	1 (1.3)		
Concurrent Chemotherapy (%)	16 (14.5)	17 (22.7)	0.222	0.210
<i>Line of Treatment (%)</i>			0.162	0.352
1	43 (39.1)	39 (52.0)		
2	45 (40.9)	29 (38.7)		
3	17 (15.5)	6 (8.0)		
4 or more	5 (4.5)	1 (1.3)		
<i>Rx Year (%)</i>			0.126	0.374
Pre 2016	10 (9.1)	7 (9.3)		
2016	22 (20.0)	6 (8.0)		
2017	40 (36.4)	36 (48.0)		
2018	38 (34.5)	26 (34.7)		
Completed Study (%)	72 (65.5)	49 (65.3)	1.000	0.003
Drop-Out (%)	33 (30.0)	25 (33.3)	0.750	0.072
Total Follow Time mo* (mean (SD))	66.9 (53.3)	59.2 (49.3)	0.322	0.150
Patient (>5 years follow time) (%)	49 (44.5)	29 (38.7)	0.520	0.119
Follow up at Rx mo* (mean (SD))	17.3 (12.8)	15.6 (12.3)	0.357	0.139
<u>Outcome</u>				
Death (%)	49 (44.5)	21 (28.0)	0.034	0.349

*months; Rx corresponds to anti PD1/PD-L1 therapy

Supplemental Tables for:

Analysis of real-world data to investigate the impact of race and ethnicity on response to PD-1 and PD-L1 inhibitors in advanced NSCLC

Kristin Ayers et al.

Table S4. Group Characteristics After Matching

	White	African American	p-value	SMD
n	75	75		
<u>Clinical Variables</u>				
BMI (mean (SD))	28.5 (6.1)	26.7 (6.2)	0.089	0.279
Age at Rx Initiation (mean (SD))	71.1 (9.0)	65.0 (9.4)	<0.001	0.664
Age at Rx Initiation in Years (%)			0.009	0.576
<50	0 (0.0)	1 (1.3)		
50-64	20 (26.7)	38 (50.7)		
65-74	31 (41.3)	24 (32.0)		
75+	24 (32.0)	12 (16.0)		
Gender (%)			0.623	0.107
Female	33 (44.0)	37 (49.3)		
Male	42 (56.0)	38 (50.7)		
Smoking Status (%)			0.060	0.456
Current Smoker	24 (32.0)	37 (49.3)		
Former Smoker	43 (57.3)	31 (41.3)		
Never Smoker	8 (10.7)	5 (6.7)		
Not Reported	0 (0.0)	2 (2.7)		
Histology (%)			0.335	0.243
Non-squamous cell carcinoma	58 (77.3)	50 (66.7)		
Squamous cell carcinoma	13 (17.3)	20 (26.7)		
NSCLC, Nos	4 (5.3)	5 (6.7)		
PDL1 Status (%)			0.137	0.330
Negative	20 (26.7)	12 (16.0)		
Not tested	28 (37.3)	39 (52.0)		
Positive	27 (36.0)	24 (32.0)		
Targeted Mutation EGFR/ALK (%)			0.142	0.327
Mutation Absent	49 (65.3)	43 (57.3)		
Mutation Present	8 (10.7)	4 (5.3)		
Not tested	18 (24.0)	28 (37.3)		
Comorbidities (%)			0.053	0.404
Asthma	9 (12.0)	19 (25.3)		
COPD (including Emphysema)	32 (42.7)	21 (28.0)		
Unknown or Not reported	34 (45.3)	35 (46.7)		
<u>Treatment Variables</u>				
Drug (%)			0.322	0.309
Atezolizumab	13 (17.3)	22 (29.3)		
Nivolumab	26 (34.7)	20 (26.7)		
Pembrolizumab	34 (45.3)	32 (42.7)		

Supplemental Tables for:

Analysis of real-world data to investigate the impact of race and ethnicity on response to PD-1 and PD-L1 inhibitors in advanced NSCLC

Kristin Ayers et al.

More than one	2 (2.7)	1 (1.3)		
Concurrent Chemotherapy (%)	11 (14.7)	17 (22.7)	0.295	0.206
<i>Line of Treatment (%)</i>			0.691	0.198
1	38 (50.7)	39 (52.0)		
2	26 (34.7)	29 (38.7)		
3	8 (10.7)	6 (8.0)		
4 or more	3 (4.0)	1 (1.3)		
<i>Rx Year (%)</i>			0.113	0.407
Pre 2016	5 (6.7)	7 (9.3)		
2016	15 (20.0)	6 (8.0)		
2017	26 (34.7)	36 (48.0)		
2018	29 (38.7)	26 (34.7)		
Completed Study (%)	50 (66.7)	49 (65.3)	1.000	0.028
Drop-Out (%)	24 (32.0)	25 (33.3)	1.000	0.028
Total Follow Time mo* (mean (SD))	64.5 (49.7)	59.2 (49.3)	0.513	0.107
Patient (>5 years follow time) (%)	34 (45.3)	29 (38.7)	0.508	0.135
Follow up at RX mo* (mean (SD))	16.0 (12.4)	15.6 (12.3)	0.829	0.035
Outcome				
Death (%)	33 (44.0)	21 (28.0)	0.061	0.338

*months; Rx corresponds to anti PD1/PD-L1 therapy

Supplemental Tables for:

Analysis of real-world data to investigate the impact of race and ethnicity on response to PD-1 and PD-L1 inhibitors in advanced NSCLC

Kristin Ayers et al.

Table S5: Multivariable cox regression for the African American and White matched cohort. Those with unknown smoking status and NSCLC Nos histology were excluded due to small numbers within in these categories.

Variable/Category	n=141 (%)	TTD		OS	
		aHR (95% CI)	P-value	aHR (95% CI)	P-value
<i>Race/Ethnicity</i>					
White	73 (51.8)	Ref	-	Ref	-
African American	68 (48.2)	0.51 (0.31-0.86)	0.011	0.53 (0.28-1.01)	0.054
Age at Rx Initiation (yrs)	141 (100)	0.98 (0.95-1.01)	0.180	1.00 (0.96-1.04)	0.940
BMI	141 (100)	0.95 (0.91-1.00)	0.040	0.95 (0.90-1.01)	0.100
<i>Gender</i>					
Female	66 (46.8)	Ref	-	Ref	-
Male	75 (53.2)	1.32 (0.81-2.16)	0.263	1.79 (0.98-3.27)	0.057
<i>Smoking Status</i>					
Smoker*	128 (90.8)	Ref	-	Ref	-
Never Smoker	13 (9.2)	1.32 (0.59-2.95)	0.496	1.31 (0.47-3.66)	0.610
<i>PDL1 Status</i>					
Negative	32 (22.7)	Ref	-	Ref	-
Not tested	61 (43.3)	0.67 (0.35-1.29)	0.234	0.48 (0.23-1.00)	0.050
Positive	48 (34.0)	0.66 (0.34-1.27)	0.216	0.40 (0.18-0.90)	0.027
<i>Targeted Mutation EGFR/ALK</i>					
Mutation Absent	88 (62.4)	Ref	-	Ref	-
Mutation Present	12 (8.5)	0.92 (0.32-2.68)	0.877	1.52 (0.49-4.69)	0.465
Not tested	41 (29.1)	1.09 (0.48-2.48)	0.836	1.17 (0.44-3.10)	0.746
<i>Histology</i>					
Nonsquamous cc**	107 (75.9)	Ref	-	Ref	-
Squamous cell cc**	34 (24.1)	0.67 (0.29-1.56)	0.355	0.60 (0.22-1.68)	0.332
<i>Line of Treatment</i>					
First	71 (50.4)	Ref	-	Ref	-
Second or Higher	70 (49.6)	1.23 (0.72-2.12)	0.448	1.37 (0.69-2.74)	0.370
<i>Concurrent Chemotherapy</i>					
No	115 (81.6)	Ref	-	Ref	-
Yes	26 (18.4)	0.48 (0.22-1.07)	0.073	0.44 (0.17-1.16)	0.095
<i>Disease Comorbidities</i>					
None Reported	64 (45.4)	Ref	-	Ref	-
Asthma	27 (19.1)	1.05 (0.56-1.97)	0.886	0.84 (0.35-1.99)	0.692
COPD (inc. Emphysema)	50 (35.5)	0.69 (0.40-1.21)	0.199	0.90 (0.47-1.72)	0.760

*Current or Former Smoker; **cell carcinoma; Rx corresponds to anti PD1/PD-L1 therapy

Supplemental Tables for:

Analysis of real-world data to investigate the impact of race and ethnicity on response to PD-1 and PD-L1 inhibitors in advanced NSCLC

Kristin Ayers et al.

Table S6. HRs for single variable cox regression for OS in smokers without EGFR/ALK mutations (n=195).

Variable/Category	n (%)	HR OS (95% CI)	P-value
Age at Rx Initiation	195 (100)	1.01 (0.98-1.03)	0.644
<i>Age at Rx Category (yrs)</i>			
<50	4 (2.1)	-	-
50-64	77 (39.5)	Ref	-
65-74	72 (36.9)	1.06 (0.63-1.80)	0.825
75+	42 (21.5)	0.97 (0.51-1.85)	0.920
BMI	195 (100)	0.99 (0.95-1.02)	0.474
<i>Gender</i>			
Female	86 (44.1)	Ref	-
Male	109 (55.9)	1.43 (0.88-2.30)	0.146
<i>Race/Ethnicity</i>			
White	91 (46.7)	Ref	-
Asian	10 (5.1)	0.56 (0.17-1.80)	0.329
African American	65 (33.3)	0.55 (0.31-0.97)	0.039
Hispanic	25 (12.8)	0.78 (0.40-1.52)	0.466
Other/Unknown	4 (2.1)	-	-
<i>Histology</i>			
Nonsquamous cell carcinoma	139 (71.6)	Ref	-
Squamous cell carcinoma	44 (22.7)	0.75 (0.41-1.35)	0.330
NSCLC, Nos	11 (5.7)	1.24 (0.45-3.43)	0.676
<i>PDL1 Status</i>			
Negative	45 (23.1)	Ref	-
Not tested	89 (45.6)	0.92 (0.53-1.62)	0.782
Positive	61 (31.3)	0.55 (0.28-1.10)	0.090
<i>Line of Treatment</i>			
First	89 (45.6)	Ref	-
Second or Higher	106 (54.4)	1.38 (0.85-2.25)	0.195
<i>Concurrent with Chemotherapy</i>			
No	160 (82.5)	Ref	-
Yes	34 (17.5)	0.86 (0.44-1.68)	0.651
<i>Disease Comorbidities</i>			
None Reported	89 (45.6)	Ref	-
Asthma	35 (17.9)	0.90 (0.47-1.72)	0.753
COPD (inc. Emphysema)	71 (36.4)	0.97 (0.58-1.63)	0.920

Rx corresponds to anti PD1/PD-L1 therapy

Supplemental Tables for:

Analysis of real-world data to investigate the impact of race and ethnicity on response to PD-1 and PD-L1 inhibitors in advanced NSCLC

Kristin Ayers et al.

Table S7. Subgroup analysis for First and Higher Line of Treatment with single variable cox regression for OS.

Variable/Category	First LOT			Second or Higher LOT		
	n=113	HR OS (95% CI)	Pvalue	n=136	HR OS (95% CI)	Pvalue
Age at Rx Initiation	113 (100)	1.01 (0.97-1.05)	0.622	136 (100)	1.02 (0.99-1.05)	0.258
<i>Age Rx Category (yrs)</i>						
<50	1 (0.9)	-	-	6 (4.4)	-	-
50-64	39 (34.5)	Ref	-	53 (39.0)	Ref	-
65-74	41 (36.3)	0.82 (0.35-1.95)	0.654	55 (40.4)	1.18 (0.66-2.09)	0.582
75+	32 (28.3)	1.28 (0.55-2.95)	0.570	22 (16.2)	0.98 (0.46-2.10)	0.960
BMI	113 (100)	0.97 (0.92-1.03)	0.339	136 (100)	0.99 (0.95-1.03)	0.694
<i>Gender</i>						
Female	56 (49.6)	Ref	-	66 (48.5)	Ref	-
Male	57 (50.4)	2.14 (1.03-4.45)	0.042	70 (51.5)	1.34 (0.80-2.25)	0.259
<i>Smoking Status</i>						
Smoker*	95 (84.1)	Ref	-	116 (85.3)	Ref	-
Never Smoker	18 (15.9)	0.64 (0.22-1.82)	0.399	20 (14.7)	0.63 (0.27-1.47)	0.285
Not reported	2 (1.8)	-	-	2(1.5)	-	-
<i>Race/Ethnicity</i>						
White	43 (38.1)	Ref	-	67 (49.3)	Ref	-
Asian	14 (12.4)	0.27 (0.06-1.16)	0.078	10 (7.4)	0.77 (0.27-2.18)	0.620
African American	39 (34.5)	0.61 (0.27-1.37)	0.229	36 (26.5)	0.58 (0.30-1.13)	0.110
Hispanic	14 (12.4)	0.63 (0.21-1.89)	0.408	21 (15.4)	0.74 (0.36-1.49)	0.397
Other/Unknown	3 (1.8)	-	-	2 (2.2)	-	-
<i>Histology</i>						
Nonsquamous cc**	88 (77.9)	Ref	-	101 (74.3)	Ref	-
Squamous cc**	18 (15.9)	1.77 (0.76-4.14)	0.189	30 (22.1)	0.59 (0.30-1.17)	0.133
NSCLC, Nos	7 (6.2)	-	-	5 (3.7)	-	-
<i>Targeted Mutation EGFR/ALK</i>						
Mutation Absent	76 (67.3)	Ref	-	81 (59.6)	Ref	-
Mutation Present	7 (6.2)	-	-	18 (13.2)	1.70 (0.81-3.54)	0.160
Not tested	30 (26.5)	2.11 (0.99-4.05)	0.053	37 (27.2)	0.67 (0.35-1.28)	0.221
<i>PDL1 Status</i>						
Negative	23 (20.4)	Ref	-	29 (21.3)	Ref	-
Not tested	37 (32.7)	0.64 (0.25-1.63)	0.353	82 (60.3)	1.27 (0.65-2.48)	0.476
Positive	53 (46.9)	0.75 (0.31-1.79)	0.516	25 (18.4)	0.46 (0.17-1.24)	0.124
<i>Concurrent with Chemotherapy</i>						
No	78 (69)	Ref	-	123 (90.4)	Ref	-
Yes	35 (31)	1.16 (0.56-2.43)	0.686	13 (9.6)	0.14 (0.02-0.98)	0.047
<i>Disease Comorbidities</i>						
None Reported	59 (52.2)	Ref	-	69 (50.7)	Ref	-
Asthma	23 (20.4)	0.71 (0.27-1.83)	0.478	21 (15.4)	1.10 (0.51-2.41)	0.802
COPD (Emphysema)	31 (27.4)	1.31 (0.60-2.86)	0.496	46 (33.8)	0.97 (0.55-1.70)	0.911

*Current or Former Smoker; **cell carcinoma; Rx corresponds to anti PD1/PD-L1 therapy

Supplemental Tables for:

Analysis of real-world data to investigate the impact of race and ethnicity on response to PD-1 and PD-L1 inhibitors in advanced NSCLC

Kristin Ayers et al.

Table S8. HRs for single variable cox regression for OS within Race.

Variable/Category	White			African American		
	n=110(%)	HR OS (95% CI)	p-value	n=75 (%)	HR OS (95% CI)	p-value
Age at Rx Initiation	110 (100)	1.02 (0.99-1.06)	0.236	75 (100)	0.97 (0.92-1.02)	0.233
<i>Age Rx Category (yrs)</i>						
<50	0 (0.0)	-	-	1 (1.3)	-	-
50-64	30 (27.3)	Ref	-	38 (50.7)	Ref	-
65-74	49 (44.5)	1.17 (0.58-2.33)	0.664	24 (32)	0.56 (0.20-1.56)	0.266
75+	31 (28.2)	1.06 (0.48-2.33)	0.879	12 (16)	0.48 (0.11-2.11)	0.330
BMI	110 (100)	0.99 (0.94-1.03)	0.586	75 (100)	0.95 (0.87-1.03)	0.198
<i>Gender</i>						
Female	55 (50)	Ref	-	37 (49.3)	Ref	-
Male	55 (50)	1.59 (0.90-2.82)	0.111	38 (50.7)	1.76 (0.73-4.26)	0.207
<i>Smoking Status</i>						
Smoker*	98 (89.1)	Ref	-	68 (90.1)	-	-
Never Smoker	12 (10.9)	0.69 (0.25-1.91)	0.472	5 (6.7)	-	-
Not Reported	0 (0.0)	-	-	2 (2.7)	-	-
<i>Histology</i>						
Nonsquamous cell cc**	88 (80)	Ref	-	50 (66.7)	Ref	-
Squamous cell cc**	18 (16.4)	1.27 (0.62-2.64)	0.515	20 (26.7)	0.50 (0.17-1.49)	0.210
NSCLC, Nos						
<i>Targeted Mutation EGFR/ALK</i>						
Mutation Absent	74 (67.3)	Ref	-	43 (57.3)	Ref	-
Mutation Present	12 (10.9)	2.00 (0.87-4.59)	0.101	4 (5.3)	-	-
Not tested	24 (21.8)	2.01 (1.04-3.88)	0.037	28 (37.3)	0.55 (0.20-1.53)	0.254
<i>PDL1 Status</i>						
Negative	28 (25.5)	Ref	-	12 (16.0)	Ref	-
Not tested	47 (42.7)	0.69 (0.34-1.37)	0.286	39 (52.0)	1.62 (0.46-5.71)	0.449
Positive	35 (31.8)	0.44 (0.20-0.97)	0.042	24 (32.0)	1.11 (0.26-4.63)	0.891
<i>Line of Treatment</i>						
First	43 (39.1)	Ref	-	39 (52.0)	Ref	-
Second or Higher	67 (60.9)	1.25 (0.68-2.26)	0.472	36 (48.0)	1.21 (0.51-2.88)	0.666
<i>Concurrent Chemotherapy</i>						
No	94 (85.5)	Ref	-	58 (77.3)	Ref	-
Yes	16 (14.5)	0.75 (0.32-1.76)	0.506	17 (22.7)	0.61 (0.18-2.09)	0.431
<i>Disease Comorbidities</i>						
None Reported	53 (48.2)	Ref	-	35 (46.7)	Ref	-
Asthma	11 (10.0)	0.74 (0.25-2.14)	0.576	19 (25.3)	1.00 (0.36-2.76)	0.997
COPD (Emphysema)	46 (41.8)	1.26 (0.70-2.26)	0.444	21 (28.0)	0.64 (0.22-1.89)	0.421

*Current or Former Smoker; **cell carcinoma; Rx corresponds to anti PD1/PD-L1 therapy